Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Novel Compound Promising Alternative to Current Opioids
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus | National Eczema Association
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
Kappa opioid receptor binding affinity and the effects on... | Download Scientific Diagram
Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain | Journal of Medicinal Chemistry
SEC Filing | Cara Therapeutics
Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists
Frontiers | Advances in Achieving Opioid Analgesia Without Side Effects
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Frontiers | The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
PDF) The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Open AccessJournals | List of Open Access Journals | Juniper Publishers
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits - Kim - 2022 - Experimental Dermatology - Wiley Online Library
Kappa opioid receptor binding affinity and the effects on... | Download Scientific Diagram
CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing? | Semantic Scholar
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Frontiers | The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
